Anju Expands TA Scan Platform
Company to integrate European diversity data from the UK and demographics data from France and Spain.
Anju, a clinical technical solutions provider, announced the expansion of its TA Scan platform through the integration of European diversity data from the UK and demographics data from France and Spain. According to a company press release, TA Scan enables users to visualize essential data, such as ethnicity, socio-economic information, and site/investigator experience, all on a single map.
"TA Scan's expansion into European diversity data underscores our commitment to helping clinical research professionals meet their global study diversification goals," said Barbara Argibay, VP, development, data division, Anju. "Empowering users to optimize recruitment strategies, site/investigator/KOL selection, and diversity initiatives with ease, while maintaining the highest standards of data security and privacy."
Reference: Anju's TA Scan Expands Global Reach with European Diversity Data Integration. PR Newswire. October 17, 2023, Accessed October 20, 2023. https://www.prnewswire.com/news-releases/anjus-ta-scan-expands-global-reach-with-european-diversity-data-integration-301959425.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
